Psoriasis 2 C1864497
A common autoimmune skin disease characterized by inflamed, scaly patches caused by overactive immune cells. It tends to run in families and can develop at any age. Treatment aims to reduce inflammation with creams, pills, or injections.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and nutritional therapy
Treatment options should be discussed with a qualified healthcare provider.
Topical vitamin D analogs
Calcipotriene or calcipotriol creams to normalize skin cell growth and reduce scaling in plaque psoriasis.
Topical corticosteroids
Potent topical corticosteroids for rapid control of inflammation and itching in moderate-to-severe plaque lesions.
Additional treatment options
Excimer laser therapy
Targeted laser treatment delivering UVB light directly to psoriatic plaques for localized disease control.
procedureSmoking cessation and alcohol reduction
Elimination of tobacco use and limitation of alcohol consumption, as both are known triggers for psoriasis exacerbations.
lifestyleCoal tar preparations
Topical coal tar formulations with anti-inflammatory and anti-scaling properties, often combined with phototherapy.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Psoriasis 2 C1864497?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Menter A, Strober BE, Kaplan DH, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019.
Benton EC, Cork MJ, Bowen F, Dickinson CJ. Topical calcipotriol in psoriasis: an updated meta-analysis of clinical trials. Br J Dermatol. 2018.
Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis. Br J Dermatol. 2017.
Boehncke WH, Schon MP. Psoriasis and other papulosquamous diseases. Lancet. 2020.
Medication Comparisons
Compare medications used to treat Psoriasis 2 C1864497. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy